Diligence and valuation, grounded in evidence.
For investors and life-science ventures, AHRM brings the same rigor we apply to health economics to the questions that decide a deal: does the science hold up, will payers reimburse it, and what is the asset actually worth? We assess the evidence and the market with equal seriousness — and treat every engagement confidentially.
Investment support across the evidence and the market.
Engaged individually or as an integrated diligence package.
Interrogate the science
- Clinical evidence & trial design review
- Endpoint and probability-of-success assessment
- Regulatory pathway risk
- Competitive & pipeline landscape
Test the payer case
- Reimbursement & coverage likelihood
- Value-story and HTA-readiness assessment
- Pricing potential & access barriers
- Health-economic risk to the thesis
Put a number on it
- Asset & company valuation
- Risk-adjusted NPV modeling
- Comparable transactions & benchmarks
- Scenario & sensitivity analysis
Size the opportunity
- Epidemiology-based market sizing
- Revenue & uptake forecasting
- Addressable-population modeling
- Real-world data to ground assumptions
Map the access reality
- Payer environment analysis
- Pricing benchmarks by market
- Coverage-policy & HTA precedent
- Access-barrier identification
Tell it credibly
- Pitch deck & investor narrative development
- Evidence-backed value story
- Data-room & diligence-response support
- Scientific and economic messaging
We read the science and the market — because we work in both.
Most diligence providers are strong on one side: clinical or commercial. AHRM sits at the intersection. We run trials and build the health-economic case for a living, so when we assess an asset for you, we're evaluating it the way the regulators, payers, and HTA bodies who ultimately decide its fate will.
- ScienceWe know what a credible trial and endpoint look like
- MarketWe know what payers actually reimburse and why
- ValueWe translate both into a defensible number
- TrustIndependent, confidential, conflict-free assessment
Scoped to your decision and your timeline.
Scope
A confidential conversation to understand the asset, the decision in front of you, and how fast you need answers.
Assess
We evaluate the science, the market-access case, and the numbers — drawing on evidence we can generate and interrogate first-hand.
Deliver
A clear, defensible view you can act on or put in front of your partners — with the underlying assumptions laid bare.
Start a confidential conversation.
Tell us about the asset or the decision, and we'll outline how we can help — and how quickly.
Contact usRaleigh, NC
+1 919-758-8203
Toll-free
1-888-704-5242